FarmaSino 's 2022 year-end summary conference

On January 8, FarmaSino Co., Ltd. held the 2022 annual work summary and advanced commendation conference in the conference room of the headquarters building. At the beginning of the meeting, the leaders of various departments reported the business results in 2022, comprehensively analyzed the gains and losses in the work, and planned and looked forward to the work in 2023. Next, the company recognized the advanced individuals and teams that emerged this year.

The last session of the conference was delivered by Yan Libo, Chairman of FarmaSino, who introduced to all employees the company's brilliant performance in 2022, and the company's sales exceeded 200 million US dollars for the first time since its establishment, an increase of more than 30% year-on-year, achieving a milestone leap in business performance.

Looking back on 2022, due to multiple factors, the international economic situation is grim, but the company relies on the "moat" forged by years of deep cultivation in the field of internationalization of biomedical health products, relying on deep brand advantages and in-depth cooperative relations in multiple dimensions such as customers, suppliers, markets, products, etc., overcoming various external unfavorable factors and achieving contrarian excess growth, which fully gives us confidence and ability affirmation, so that all employees further recognize the company's competitive advantages in the field of internationalization of biomedical health products.

Mr. Yan further commented on the annual debriefing of each business segment and each functional department, and gave a high evaluation and full affirmation of the achievements achieved this year, and also sent a message to all employees, the company will unswervingly take sustainable and stable development as the company's eternal theme, the business department in consolidating its own advantages at the same time to actively explore the market, constantly optimize the customer structure to find new business growth points, functional departments should closely around the company's established strategy to do a good job in the front-line development of the business department logistics support service work, Prevent and control risks, reduce costs and increase efficiency. Finally, Mr. Yan called on the whole company to unite and work hard to reach a higher level in 2023!

A new journey in 2023

Only seize the day and live up to Shaohua

Career co-creation, meet the future

FarmaSino Co., Ltd. is a member of Jiangsu Huihong International Group (stock code: 600981), one of the top 500 companies in China, mainly engaged in the internationalization of biomedicine, and its products are sold in more than 120 countries and regions around the world. With an annual export volume of more than 200 million US dollars and annual sales of nearly 1.5 billion yuan, the company has been awarded the "Top 10 Export Enterprises of Western Patent Medicine" by the China Medical Insurance Chamber of Commerce for 9 consecutive years and among the "Top 100 Chinese Pharmaceutical Internationalization Enterprises" for 6 consecutive years. In 2017, the company was successfully elected as the vice president unit of China Chamber of Commerce for Import and Export of Medicines and Health Products. With high-quality products, advanced technology and high-end services, New Century Pharmaceutical makes unremitting efforts to promote the development of China's pharmaceutical industry and build an international biopharmaceutical enterprise integrating R&D, production and international trade.

FarmaSino Co., Ltd. is a wholly-owned subsidiary of Jiangsu Kaiyuan Pharmaceutical Co., Ltd., providing one-stop technical services for the R&D and registration of generic drugs and innovative drugs, establishing industry-university-research cooperation with many universities and scientific research units such as China Pharmaceutical University and Nanjing University of Chinese Medicine, and reaching strategic cooperation with Sinopharm Group, Guangzhou Pharmaceutical Group, Guobang Pharmaceutical Group, Dingtai Pharmaceutical Research Group, etc. In 2021, the company obtained the B certificate of "Drug Manufacturing License" as a marketing authorization holder (MAH). The company has won the national "high-tech enterprise" certification, CNAS laboratory accreditation, national intellectual property management system certification, established Jiangsu Province enterprise graduate workstation, and won the honorary titles of Jiangsu Top 100 Science and Technology Service Institutions, Nanjing Engineering Technology Research Center for Consistency Evaluation of Generic Drugs, Nanjing Engineering Research Center, Nanjing Credit Management Demonstration Enterprise and so on.